Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Packard

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Diabetes|March 31, 2007
Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factorNaveed Sattar, Alex McConnachie, Ian Ford, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 11, 2005
Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemiaMartin Adiels, Jan Borén, Muriel J Caslake, et al.
Journal of Lipid Research|October 19, 2004
A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractionsMartin Adiels, Chris Packard, Muriel J Caslake, et al.
Journal of Lipid Research|July 7, 2009
Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trialNirupa R Matthan, Nancy Resteghini, Michele Robertson, et al.
Journal of the American Society of Nephrology : JASN|October 28, 2005
Effect of pravastatin in people with diabetes and chronic kidney diseaseMarcello Tonelli, Anthony Keech, Jim Shepherd, et al.
The Lancet Regional Health. Western Pacific|October 13, 2025
Redefining the association of triglycerides with all-cause and Cardiovascular Disease Mortality in the Chinese population: a nationwide, population-based, prospective cohort study of 3.8 million Chinese adultsGuangyu Li, Linkang He, Xueke Bai, et al.
Circulation|July 7, 2005
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary diseaseMarcello Tonelli, Chris Isles, Timothy Craven, et al.
Diabetes, Obesity & Metabolism|April 12, 2019
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemiaMartin Adiels, Marja-Riitta Taskinen, Elias Björnson, et al.
Journal of Clinical Lipidology|January 10, 2020
Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjectsMarja-Riitta Taskinen, Elias Björnson, Linda Andersson, et al.
Lancet (London, England)|May 4, 2010
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies, Alexander Thompson, Pei Gao, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Diabetes|March 31, 2007
Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factorNaveed Sattar, Alex McConnachie, Ian Ford, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 11, 2005
Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemiaMartin Adiels, Jan Borén, Muriel J Caslake, et al.
Journal of Lipid Research|October 19, 2004
A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractionsMartin Adiels, Chris Packard, Muriel J Caslake, et al.
Journal of Lipid Research|July 7, 2009
Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trialNirupa R Matthan, Nancy Resteghini, Michele Robertson, et al.
Journal of the American Society of Nephrology : JASN|October 28, 2005
Effect of pravastatin in people with diabetes and chronic kidney diseaseMarcello Tonelli, Anthony Keech, Jim Shepherd, et al.
The Lancet Regional Health. Western Pacific|October 13, 2025
Redefining the association of triglycerides with all-cause and Cardiovascular Disease Mortality in the Chinese population: a nationwide, population-based, prospective cohort study of 3.8 million Chinese adultsGuangyu Li, Linkang He, Xueke Bai, et al.
Circulation|July 7, 2005
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary diseaseMarcello Tonelli, Chris Isles, Timothy Craven, et al.
Diabetes, Obesity & Metabolism|April 12, 2019
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemiaMartin Adiels, Marja-Riitta Taskinen, Elias Björnson, et al.
Journal of Clinical Lipidology|January 10, 2020
Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjectsMarja-Riitta Taskinen, Elias Björnson, Linda Andersson, et al.
Lancet (London, England)|May 4, 2010
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies, Alexander Thompson, Pei Gao, et al.
Pageof 3